Knight Therapeutics (TSE:GUD) Target Increased
In analysts report issued to clients by Scotia Capital on 23 December, Knight Therapeutics (TSE:GUD) had its target price boosted to $10.50. The firm presently has Outperform rating on the stock.
The target increase is well-received by investors, as TSE:GUD is currently trading 0.99% higher at $10.16 as of 3:58 AM New York time. Knight Therapeutics shares have [From2] 0% in the last 200 days, while the S&P 500 has surged 13.64% during the same time.
Out of 9 brokers covering Knight Therapeutics, 0 rate it a Buy, 0 indicate a Hold while 0 suggest a Sell. The highest target is $8.89 and the lowest is $6.48 according to Thomson/First Call. The 12-month mean target is $7.78, which means downside potential of 23.43% over the current price.
Knight Therapeutics (TSE:GUD) Profile
Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally.
Knight Therapeutics (TSE:GUD) traded up 0.99% on 23 December, hitting $10.16. A total of 231,957 shares of the company’s stock traded hands. This is down from average of 448,957 shares. Knight Therapeutics has a 52 week low of $5.89 and a 52 week high of $11.03. The company has a market cap of $1.36 billion and a P/E ratio of 72.59.
Get the latest Knight Therapeutics (TSE:GUD) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Knight Therapeutics (TSE:GUD) Had Its Price Objective Raises by Equity Research Analysts at Scotia Capital to $10.50 appeared first on Octafinance.